• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

替考拉宁对金黄色葡萄球菌引起的小鼠大腿感染模型的药代动力学/药效学评价。

Pharmacokinetic/pharmacodynamic evaluation of teicoplanin against Staphylococcus aureus in a murine thigh infection model.

机构信息

Department of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan.

Department of Clinical Pharmacotherapy, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.

出版信息

J Glob Antimicrob Resist. 2021 Mar;24:83-87. doi: 10.1016/j.jgar.2020.11.014. Epub 2020 Dec 5.

DOI:10.1016/j.jgar.2020.11.014
PMID:33290889
Abstract

OBJECTIVES

Pharmacokinetic/pharmacodynamic (PK/PD) analysis using murine infection models is a well-established methodology for optimising antimicrobial therapy. Therefore, we investigated the PK/PD indices of teicoplanin againstStaphylococcus aureus using a murine thigh infection model.

METHODS

Mice were rendered neutropenic by administration of a two-step dosing of cyclophosphamide. Then, isolates of methicillin-susceptibleS. aureus (MSSA) or methicillin-resistant S. aureus (MRSA) were inoculated into the thighs of neutropenic mice. PK/PD analyses were performed by non-linear least-squared regression using the MULTI program.

RESULTS

Target values offC/MIC (r = 0.94) of teicoplanin for static effect and 1 log kill against MSSA were 4.44 and 15.44, respectively. Target values of fAUC/MIC (r = 0.92) of teicoplanin for static effect and 1 log kill against MSSA were 30.4 and 70.56, respectively. Target values of fC/MIC (r = 0.91) of teicoplanin for static effect and 1 log kill against MRSA were 8.92 and 14.16, respectively. Target values of fAUC/MIC (r = 0.92) of teicoplanin for static effect and 1 log kill against MRSA were 54.8 and 76.4, respectively.

CONCLUSION

These results suggest thatfC/MIC and fAUC/MIC are useful PK/PD indices of teicoplanin against MSSA and MRSA.

摘要

目的

使用小鼠感染模型进行药代动力学/药效学(PK/PD)分析是优化抗菌治疗的一种成熟方法。因此,我们使用小鼠大腿感染模型研究了替考拉宁对金黄色葡萄球菌的 PK/PD 指标。

方法

通过两步给予环磷酰胺使小鼠中性粒细胞减少。然后,将耐甲氧西林金黄色葡萄球菌(MSSA)或耐甲氧西林金黄色葡萄球菌(MRSA)分离株接种到中性粒细胞减少小鼠的大腿中。使用 MULTI 程序通过非线性最小二乘回归进行 PK/PD 分析。

结果

替考拉宁针对 MSSA 的静态效果和 1 对数杀灭的 fC/MIC 目标值分别为 4.44 和 15.44。替考拉宁针对 MSSA 的静态效果和 1 对数杀灭的 fAUC/MIC 目标值分别为 30.4 和 70.56。替考拉宁针对 MRSA 的静态效果和 1 对数杀灭的 fC/MIC 目标值分别为 8.92 和 14.16。替考拉宁针对 MRSA 的静态效果和 1 对数杀灭的 fAUC/MIC 目标值分别为 54.8 和 76.4。

结论

这些结果表明,fC/MIC 和 fAUC/MIC 是替考拉宁针对 MSSA 和 MRSA 的有用 PK/PD 指标。

相似文献

1
Pharmacokinetic/pharmacodynamic evaluation of teicoplanin against Staphylococcus aureus in a murine thigh infection model.替考拉宁对金黄色葡萄球菌引起的小鼠大腿感染模型的药代动力学/药效学评价。
J Glob Antimicrob Resist. 2021 Mar;24:83-87. doi: 10.1016/j.jgar.2020.11.014. Epub 2020 Dec 5.
2
In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.羊毛硫抗生素NAI-107在中性粒细胞减少小鼠大腿感染模型中的体内药代动力学和药效学
Antimicrob Agents Chemother. 2015 Feb;59(2):1258-64. doi: 10.1128/AAC.04444-14. Epub 2014 Dec 15.
3
Pharmacodynamics of teicoplanin against MRSA.替考拉宁对耐甲氧西林金黄色葡萄球菌的药效学。
J Antimicrob Chemother. 2017 Dec 1;72(12):3382-3389. doi: 10.1093/jac/dkx289.
4
Investigation on rifampicin administration from the standpoint of pharmacokinetics/pharmacodynamics in a neutropenic murine thigh infection model.在中性粒细胞减少小鼠大腿感染模型中,从药代动力学/药效学角度对利福平给药进行的研究。
J Infect Chemother. 2016 Jun;22(6):387-94. doi: 10.1016/j.jiac.2016.02.011. Epub 2016 Mar 27.
5
Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.新型头孢菌素PPI-0903(TAK-599)在小鼠大腿和肺部感染模型中对耐甲氧西林金黄色葡萄球菌的药效学:体内药代动力学-药效学靶点的鉴定
Antimicrob Agents Chemother. 2006 Apr;50(4):1376-83. doi: 10.1128/AAC.50.4.1376-1383.2006.
6
In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.在中性粒细胞减少小鼠大腿模型中,针对肺炎链球菌和金黄色葡萄球菌,对两种细菌拓扑异构酶抑制剂ACT - 387042和ACT - 292706进行体内药效学靶点研究。
Antimicrob Agents Chemother. 2016 May 23;60(6):3626-32. doi: 10.1128/AAC.00363-16. Print 2016 Jun.
7
Pharmacodynamics of Omadacycline against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model.奥马环素对中性粒细胞减少症小鼠大腿感染模型中金黄色葡萄球菌的药效学研究。
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00624-19. Print 2019 Jul.
8
In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.在一项小鼠大腿感染模型中,评估妥珠单抗(原 CS-023)对铜绿假单胞菌和耐甲氧西林金黄色葡萄球菌的体内药效学活性。
Antimicrob Agents Chemother. 2010 Dec;54(12):5298-302. doi: 10.1128/AAC.00267-10. Epub 2010 Oct 4.
9
Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.新型氨甲基环素类抗生素 KBP-7072 在中性粒细胞减少症小鼠肺炎模型中抗金黄色葡萄球菌和肺炎链球菌的药代动力学/药效学评价。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02404-18. Print 2019 Mar.
10
Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model.新型FabI抑制剂AFN-1252在小鼠大腿感染模型中对甲氧西林敏感金黄色葡萄球菌和耐甲氧西林金黄色葡萄球菌的药代动力学、药效学及疗效
J Chemother. 2013 Feb;25(1):26-31. doi: 10.1179/1973947812Y.0000000061.

引用本文的文献

1
Pharmacokinetic/pharmacodynamic parameters of teicoplanin for predicting clinical outcome of glycopeptide-susceptible bacteraemia.替考拉宁的药代动力学/药效学参数对预测糖肽类敏感菌血症临床结局的作用
JAC Antimicrob Resist. 2025 Aug 21;7(4):dlaf151. doi: 10.1093/jacamr/dlaf151. eCollection 2025 Aug.
2
Pharmacokinetics and Target Attainment of Teicoplanin: A Systematic Review.替考拉宁的药代动力学与达标情况:一项系统评价
Clin Pharmacokinet. 2025 Apr;64(4):467-509. doi: 10.1007/s40262-025-01483-7. Epub 2025 Mar 10.
3
The Application of Rat Models in Infections.
大鼠模型在感染中的应用。
Pathogens. 2024 May 21;13(6):434. doi: 10.3390/pathogens13060434.
4
Accuracy of Therapeutic Drug Monitoring of Teicoplanin at the Onset of Febrile Neutropenia.发热性中性粒细胞减少症发生时治疗药物监测替考拉宁的准确性。
Medicina (Kaunas). 2023 Apr 13;59(4):758. doi: 10.3390/medicina59040758.
5
Model-informed precision dosing of teicoplanin for the rapid achievement of the target area under the concentration-time curve: A simulation study.基于模型的替考拉宁精准给药以快速达到浓度-时间曲线下目标面积:一项模拟研究。
Clin Transl Sci. 2023 Apr;16(4):704-713. doi: 10.1111/cts.13484. Epub 2023 Feb 7.
6
Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models.药代动力学/药效学(PK/PD)整合模型的药效学参数
Front Vet Sci. 2022 Mar 24;9:860472. doi: 10.3389/fvets.2022.860472. eCollection 2022.
7
Pharmacokinetics and pharmacodynamics of peptide antibiotics.肽类抗生素的药代动力学和药效学。
Adv Drug Deliv Rev. 2022 Apr;183:114171. doi: 10.1016/j.addr.2022.114171. Epub 2022 Feb 18.
8
Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.替考拉宁治疗药物监测临床实践指南:日本化疗学会和日本治疗药物监测学会的共识综述。
J Antimicrob Chemother. 2022 Mar 31;77(4):869-879. doi: 10.1093/jac/dkab499.